Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients

Table 3 Univariate and multivariate analyses of overall survival in advanced gastric cancer patients receiving immunotherapy and chemotherapy

Variable	Univariate analysis		Multivariate analysis
Variable	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (≥ 60vs. < 60 years)	1.144 (0.808–1.620)	0.447
Sex (male vs. female)	0.799 (0.535–1.195)	0.274
Drinking history (yes vs. no)	1.016 (0.700–1.476)	0.932
ECOG PS (0–1 vs. 2)	0.762 (0.540–1.074)	0.120
Stage (III vs. IV)	0.739 (0.509–1.075)	0.113
Differentiation (well or moderate vs. poor)	1.169 (0.815–1.678)	0.396
PD-1⁺CD8⁺Tn % (< 21.5 vs. ≥ 21.5)	1.239(0.878–1.748)	0.223
PD-L1 CPS (< 5 vs. ≥ 5)	11.86(6.934–20.28)	< 0.001	5.224 (2.802–9.740)	< 0.001
PD-1⁺CD8⁺T % (< 21.0 vs. ≥ 21.0)	23.12 (12.63–42.34)	< 0.001	16.92 (8.505–33.65)	< 0.001
PD-1⁺CD8⁺Tm % (< 64.3 vs. ≥ 64.3)	28.93 (14.48–57.77)	< 0.001	22.82 (10.39–50.14)	< 0.001
PD-1⁺CD8⁺T/PD-1⁺CD4⁺T ratio(< 0.669 vs. 0.669)	2.966 (2.071–4.248)	< 0.001	2.640(1.734–4.019)	< 0.001

PD-1⁺CD8⁺T PD-1⁺CD8⁺ T cells, PD-1⁺CD8⁺Tm memory PD-1⁺CD8⁺ T cells, PD-1⁺CD4⁺T PD-1⁺CD4⁺ T cells, CPS combined positive score, ECOG PS Eastern Cooperative Oncology Group Performance Status

ISSN: 1475-2867